Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia.
Paiva B, Vidriales MB, Sempere A, Tarín F, Colado E, Benavente C, Cedena MT, Sánchez J, Caballero-Velazquez T, Cordón L, Garces JJ, Simoes C, Martínez-Cuadrón D, Bernal T, Botella C, Grille S, Serrano J, Rodríguez-Medina C, Algarra L, Alonso-Domínguez JM, Amigo ML, Barrios M, García-Boyero R, Colorado M, Pérez-Oteyza J, Pérez-Encinas M, Costilla-Barriga L, Sayas MJ, Pérez O, González-Díaz M, Pérez-Simón JA, Martínez-López J, Sossa C, Orfao A, San Miguel JF, Sanz MÁ, Montesinos P; PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study group.
Paiva B, et al. Among authors: gonzalez diaz m.
Leukemia. 2021 Aug;35(8):2358-2370. doi: 10.1038/s41375-021-01126-3. Epub 2021 Feb 1.
Leukemia. 2021.
PMID: 33526859